SciFluor creates proprietary best-in-class drugs based on well-understood pathways in areas of significant medical need such as ophthalmology, neuroscience and fibrotic diseases.

Our lead drug candidate, SF0166, is a small molecule integrin antagonist designed to treat retinal disease, including Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME), via topical (eye drop) administration to the eye. SF0166 is being studied in two separate multi-center, randomized, Phase 1/2 trials, in patients with DME and in patients with AMD. In addition to this drug candidate, SciFluor has earlier-stage projects in ophthalmology, neurology, and additional therapeutic areas including fibrosis.

We strategically search for drugs candidates in known pathways, that were discontinued due to challenging chemical properties, and use advanced knowledge in biochemistry to improve the drugs’ pK, efficacy and distribution.

SciFluor was launched by and is a subsidiary of Allied Minds. Allied Minds is a private investment firm that deploys capital to form, fund, manage and build companies based on market-creating technologies developed at renowned U.S. universities and federal research institutions. More information about the Boston-based company can be found at


SciFluor News

SciFluor Life Sciences Announces First Patients Dosed in Retinal Program with Investigational New Drug Application for SF0166 Topical Ophthalmic Solution
read more >

SciFluor Announces 6 New Patent Issuances Covering the Use of SF0166 Topical Ophthalmic Solution in Retinal Diseases
read more >

SciFluor Announces Positive Results of Phase 1/2 Study of SF0166 Topical Ophthalmic Solution in Diabetic Macular Edema Patients
read more >